Guardant Health (GH) | Financial Analysis & Statements
Guardant Health Inc. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
281.3M
Gross Profit
181.8M
64.63%
Operating Income
-120.8M
-42.95%
Net Income
-128.5M
-45.68%
Balance Sheet Metrics
Total Assets
2.0B
Total Liabilities
2.1B
Shareholders Equity
-99.3M
Cash Flow Metrics
Operating Cash Flow
-90.1M
Free Cash Flow
-54.2M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Guardant Health Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 982.0M | 739.0M | 563.9M | 449.5M | 373.7M |
| Cost of Goods Sold | 349.0M | 289.8M | 227.1M | 156.3M | 122.9M |
| Gross Profit | 633.0M | 449.2M | 336.9M | 293.2M | 250.7M |
| Gross Margin % | 64.5% | 60.8% | 59.7% | 65.2% | 67.1% |
| Operating Expenses | |||||
| Research & Development | 364.2M | 347.8M | 367.2M | 373.8M | 263.2M |
| Selling, General & Administrative | 706.1M | 545.1M | 451.0M | 463.8M | 398.5M |
| Other Operating Expenses | - | - | 83.4M | - | - |
| Total Operating Expenses | 1.1B | 892.8M | 901.6M | 837.6M | 661.7M |
| Operating Income | -437.2M | -443.6M | -564.7M | -544.4M | -411.0M |
| Operating Margin % | -44.5% | -60.0% | -100.1% | -121.1% | -110.0% |
| Non-Operating Items | |||||
| Interest Income | 34.1M | 53.7M | 35.4M | 6.1M | 3.9M |
| Interest Expense | 3.9M | 2.6M | 2.6M | 2.6M | 2.6M |
| Other Non-Operating Income | -10.5M | -42.6M | 53.2M | -112.6M | 25.2M |
| Pre-tax Income | -417.5M | -435.1M | -478.8M | -653.4M | -384.5M |
| Income Tax | -1.3M | 1.3M | 685.0K | 1.1M | 300.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -416.3M | -436.4M | -479.4M | -654.6M | -384.8M |
| Net Margin % | -42.4% | -59.0% | -85.0% | -145.6% | -103.0% |
| Key Metrics | |||||
| EBITDA | -373.9M | -390.1M | -433.3M | -614.9M | -359.6M |
| EPS (Basic) | $-3.32 | $-3.56 | $-4.28 | $-6.41 | $-4.00 |
| EPS (Diluted) | $-3.32 | $-3.56 | $-4.28 | $-6.41 | $-4.00 |
| Basic Shares Outstanding | 125374000 | 122745000 | 111988000 | 102178000 | 101314000 |
| Diluted Shares Outstanding | 125374000 | 122745000 | 111988000 | 102178000 | 101314000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Guardant Health Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 378.2M | 525.5M | 1.1B | 141.6M | 492.2M |
| Short-term Investments | 823.4M | 314.4M | 35.1M | 869.6M | 440.5M |
| Accounts Receivable | 132.6M | 106.9M | 88.8M | 97.3M | 97.7M |
| Inventory | 85.9M | 71.1M | 61.9M | 51.6M | 30.7M |
| Other Current Assets | 40.7M | 33.8M | 27.7M | 31.5M | 53.1M |
| Total Current Assets | 1.5B | 1.1B | 1.3B | 1.2B | 1.1B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 158.8M | 142.3M | 157.6M | 174.0M | 189.4M |
| Goodwill | 180.4M | 13.3M | 15.6M | 18.3M | 20.8M |
| Intangible Assets | 25.9M | 6.8M | 9.0M | 11.7M | 14.2M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 139.7M | 141.4M | 124.3M | 61.5M | 60.9M |
| Total Non-Current Assets | 547.6M | 430.5M | 439.3M | 418.4M | 1.1B |
| Total Assets | 2.0B | 1.5B | 1.8B | 1.6B | 2.2B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 54.4M | 38.6M | 51.7M | 68.9M | 38.5M |
| Short-term Debt | 27.7M | 29.2M | 28.0M | 21.9M | 12.9M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | 78.0M |
| Total Current Liabilities | 302.7M | 225.6M | 205.9M | 193.2M | 194.7M |
| Non-Current Liabilities | |||||
| Long-term Debt | 1.7B | 1.3B | 1.3B | 1.3B | 1.4B |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 127.8M | 92.8M | 96.0M | 9.2M | 3.9M |
| Total Non-Current Liabilities | 1.8B | 1.4B | 1.4B | 1.4B | 1.4B |
| Total Liabilities | 2.1B | 1.6B | 1.6B | 1.5B | 1.6B |
| Equity | |||||
| Common Stock | 1.0K | 1.0K | 1.0K | 1.0K | 1.0K |
| Retained Earnings | -3.0B | -2.6B | -2.1B | -1.7B | -1.0B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -99.3M | -139.6M | 158.7M | 60.2M | 645.0M |
| Key Metrics | |||||
| Total Debt | 1.7B | 1.3B | 1.4B | 1.4B | 1.4B |
| Working Capital | 1.2B | 829.5M | 1.1B | 998.4M | 919.4M |
Balance Sheet Composition
Guardant Health Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -416.3M | -436.4M | -479.4M | -654.6M | -384.8M |
| Depreciation & Amortization | 39.7M | 42.4M | 42.9M | 36.0M | 22.3M |
| Stock-Based Compensation | 166.2M | 140.4M | 90.8M | 94.7M | 151.4M |
| Working Capital Changes | -60.8M | -50.4M | -30.4M | 41.1M | -30.9M |
| Operating Cash Flow | -230.2M | -267.0M | -345.0M | -347.6M | -212.3M |
| Investing Activities | |||||
| Capital Expenditures | -48.3M | -35.1M | -20.5M | -77.5M | -75.0M |
| Acquisitions | -59.0M | - | - | - | 0 |
| Investment Purchases | -827.2M | -314.8M | -635.5M | -327.7M | -940.2M |
| Investment Sales | 307.3M | 88.6M | 1.5B | 555.0M | 952.1M |
| Investing Cash Flow | -627.2M | -261.3M | 840.2M | 149.8M | -63.2M |
| Financing Activities | |||||
| Share Repurchases | -45.0M | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 402.5M | - | - | 0 | 0 |
| Debt Repayment | - | - | - | -71.0K | -146.0K |
| Financing Cash Flow | 638.3M | -15.8M | 466.8M | -201.1M | -84.8M |
| Free Cash Flow | -233.1M | -274.9M | -345.5M | -386.9M | -284.1M |
| Net Change in Cash | -219.1M | -544.1M | 962.0M | -398.8M | -360.3M |
Cash Flow Trend
Guardant Health Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-26.47
Forward P/E
-129.08
Price to Book
-113.87
Price to Sales
12.07
PEG Ratio
-2.38
Profitability Ratios
Profit Margin
-42.39%
Operating Margin
-42.91%
Return on Equity
419.18%
Return on Assets
-15.59%
Financial Health
Current Ratio
4.84
Debt to Equity
-17.22
Beta
1.65
Per Share Data
EPS (TTM)
$-3.32
Book Value per Share
$-0.76
Revenue per Share
$7.83
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| GH | 11.5B | -26.47 | -113.87 | 419.18% | -42.39% | -17.22 |
| Thermo Fisher | 174.6B | 25.84 | 3.31 | 13.52% | 15.15% | 82.91 |
| Danaher | 126.4B | 34.61 | 2.40 | 7.08% | 14.89% | 37.17 |
| Idexx Laboratories | 44.7B | 42.92 | 27.85 | 66.20% | 24.62% | 60.83 |
| Agilent Technologies | 32.7B | 25.67 | 4.76 | 19.95% | 18.26% | 51.39 |
| Waters | 30.5B | 28.90 | 7.24 | 29.28% | 20.30% | 60.28 |
Financial data is updated regularly. All figures are in the company's reporting currency.






